At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 69 enrolled
Drug / intervention
Hydrochlorothiazide (HCTZ) +4 moredrug
Likely dose
Aliskiren 150 mg (ALI 150)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Aldosterone and the Metabolic Syndrome: Renin Inhibition Versus Mineralocorticoid Receptor (MR) Antagonism
In Brief
A Phase 1 clinical trial evaluating Hydrochlorothiazide (HCTZ), Aliskiren 150 mg (ALI 150), and 3 other interventions for Metabolic Diseases and 3 related conditions. Completed, enrolled 69 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the effects of mineralocorticoid receptor (MR) antagonism and renin inhibition on glucose metabolism in humans.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Diseases, Diabetes Mellitus, Endocrine System Diseases, Glucose Metabolism Disorders
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
First PostedApr 2010
Primary CompletionJul 2012
Study CompletionSep 2013
TodayJul 2026
First PostedApr 14, 2010
Enrollment StartMar 1, 2010
Primary CompletionJul 1, 2012
Study CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.2 years ago
Interventions
Hydrochlorothiazide (HCTZ)drug
HCTZ 12.5mg daily
Aliskiren 150 mg (ALI 150)drug
Aliskiren 150mg daily
Spironolactone (SPL 25)drug
spironolactone 25mg daily
Aliskiren 300 mg (ALI 300)drug
Aliskiren 300mg daily
Spironolactone 50 mg (SPL 50)drug
Spironolactone 50 mg daily